DALLAS, April 6, 2021 /PRNewswire/ -- Lantern
Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical
company using its proprietary RADR® artificial
intelligence ("A.I.") platform to transform oncology drug discovery
and development today announced that Panna
Sharma, President and CEO of Lantern Pharma, will
participate in the 20th Annual Needham Healthcare
Conference, to be held virtually on April
12-15, 2021.
Mr. Sharma will participate in a fireside chat moderated by
Needham & Company's Alexander
Salisbury on Thursday, April
15, at 12:45 pm ET and hold
one-on-one meetings with investors throughout the four-day
event.
The live event will be accessible on
https://ir.lanternpharma.com and will be archived for 90 days.
Investors interested in scheduling a meeting with Mr. Sharma should
contact their Needham & Company representative or Lantern
Pharma investor relations.
Contact
Marek
Ciszewski, JD
Director, Investor Relations
628-777-3167
ir@lanternpharma.com
About Lantern Pharma
Lantern Pharma (LTRN) is a
clinical-stage biopharmaceutical company leveraging its proprietary
RADR® A.I. platform and machine learning to discover
biomarker signatures that identify patients most likely to respond
to its pipeline of genomically-targeted cancer therapeutics. We
believe our RADR® A.I. platform is among the world's largest A.I.
oncology datasets. Once a drug candidate is identified and
validated with the assistance of RADR® A.I., Lantern
seeks out industry partners, collaborators and leading scientific
advisors to develop genetically-targeted cancer therapeutics in
areas of high unmet clinical need. Lantern is currently developing
four drug candidates and an ADC program, including two phase 2
programs. By targeting drugs to patients whose genomic profile
identifies them as having the highest probability of benefiting
from the drug, Lantern's approach represents the potential to
deliver best-in-class outcomes. More information is available
at: www.lanternpharma.com and
Twitter @lanternpharma.
Forward-looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or our future financial performance; the potential
advantages of our RADR® platform in identifying
drug candidates and patient populations that are likely to respond
to a drug candidate; our strategic plans to advance the development
of our drug candidates and antibody drug conjugate (ADC)
development program; estimates regarding the development timing for
our drug candidates and ADC development program; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the
drug development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate; estimates regarding potential markets
and potential market sizes; sales estimates for our drug candidates
and our plans to discover and develop drug candidates and to
maximize their commercial potential by advancing such drug
candidates ourselves or in collaboration with others. Any
statements that are not statements of historical fact (including,
without limitation, statements that use words such as "anticipate,"
"believe," "contemplate," "could," "estimate," "expect," "intend,"
"seek," "may," "might," "plan," "potential," "predict," "project,"
"target," "aim," "should," "will," "would," or the negative of
these words or other similar expressions) should be considered
forward-looking statements. There are a number of important factors
that could cause our actual results to differ materially from those
indicated by the forward-looking statements, such as (i) the impact
of the COVID-19 pandemic, (ii) the risk that none of our product
candidates has received FDA marketing approval, and we may not be
able to successfully initiate, conduct, or conclude clinical
testing for or obtain marketing approval for our product
candidates; (iii) the risk that no drug product based on our
proprietary RADR A.I. platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (iv)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and
Exchange Commission on March 10,
2021. You may access our Annual Report on Form 10-K for the
year ended December 31, 2020 under
the investor SEC filings tab of our website
at www.lanternpharma.com or on the SEC's website
at www.sec.gov. Given these risks and uncertainties, we can
give no assurances that our forward-looking statements will prove
to be accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-to-participate-in-the-virtual-20th-annual-needham-healthcare-conference-301262929.html
SOURCE Lantern Pharma